Suppr超能文献

用于癌症治疗的免疫细胞伪装表面工程纳米疗法。

Immune cell-camouflaged surface-engineered nanotherapeutics for cancer management.

作者信息

Jain Naitik, Shahrukh Syed, Famta Paras, Shah Saurabh, Vambhurkar Ganesh, Khatri Dharmendra Kumar, Singh Shashi Bala, Srivastava Saurabh

机构信息

Department of Pharmaceutics, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India.

Department of Biological Sciences, National Institute of Pharmaceutical Education and Research (NIPER), Hyderabad, 500037, India.

出版信息

Acta Biomater. 2023 Jan 1;155:57-79. doi: 10.1016/j.actbio.2022.11.001. Epub 2022 Nov 5.

Abstract

Nanocarriers (NCs) have shown potential in delivering hydrophobic cytotoxic drugs and tumor-specific targeting. However, the inability to penetrate the tumor microenvironment and entrapment by macrophages has limited their clinical translation. Various cell-based drug delivery systems have been explored for their ability to improve circulation half-life and tumor accumulation capabilities. Tumors are characterized by high inflammation, which aids in tumor progression and metastasis. Immune cells show natural tumor tropism and penetration inside the tumor microenvironment (TME) and are a topic of great interest in cancer drug delivery. However, the TME is immunosuppressive and can polarize immune cells to pro-tumor. Thus, the use of immune cell membrane-coated NCs has gained popularity. Such carriers display immune cell-specific surface receptors for tumor-specific accumulation but lack cell machinery. The lack of immune cell machinery makes them unaffected by the immunosuppressive TME, meanwhile maintaining the inherent tumor tropism. In this review, we discuss the molecular mechanism behind the movement of various immune cells toward TME, the preparation and characterization of membrane-coated NCs, and the efficacy of immune cell-mimicking NCs in tumor therapy. Regulatory guidelines and the bottlenecks in clinical translation are also highlighted. STATEMENT OF SIGNIFICANCE: Nanocarriers have been explored for the site-specific delivery of chemotherapeutics. However, low systemic circulation half-life, extensive entrapment by macrophages, and poor accumulation inside the tumor microenvironment prevent the clinical translation of conventional nanotherapeutics. Immune cells possess the natural tropism towards the tumor along the chemokine gradient. Hence, coating the nanocarriers with immune cell-derived membranes can improve the accumulation of nanocarriers inside the tumor. Moreover, coating with membranes derived autologous immune cells will prevent engulfment by the macrophages.

摘要

纳米载体(NCs)在递送疏水性细胞毒性药物和肿瘤特异性靶向方面已显示出潜力。然而,无法穿透肿瘤微环境以及被巨噬细胞截留限制了它们的临床应用转化。人们已经探索了各种基于细胞的药物递送系统,以提高其循环半衰期和肿瘤蓄积能力。肿瘤的特征是具有高度炎症,这有助于肿瘤进展和转移。免疫细胞表现出天然的肿瘤嗜性并能穿透肿瘤微环境(TME),是癌症药物递送中备受关注的一个话题。然而,TME具有免疫抑制作用,可使免疫细胞极化为促肿瘤细胞。因此,使用免疫细胞膜包被的NCs受到了广泛关注。这类载体展示出用于肿瘤特异性蓄积的免疫细胞特异性表面受体,但缺乏细胞机制。缺乏免疫细胞机制使它们不受免疫抑制性TME的影响,同时保持固有的肿瘤嗜性。在本综述中,我们讨论了各种免疫细胞向TME移动背后的分子机制、膜包被NCs的制备和表征,以及免疫细胞模拟NCs在肿瘤治疗中的疗效。还强调了监管指南和临床应用转化中的瓶颈。重要性声明:人们已经探索了纳米载体用于化疗药物的位点特异性递送。然而,低全身循环半衰期、被巨噬细胞大量截留以及在肿瘤微环境内蓄积不佳阻碍了传统纳米疗法的临床应用转化。免疫细胞沿趋化因子梯度对肿瘤具有天然嗜性。因此,用免疫细胞衍生的膜包被纳米载体可以提高纳米载体在肿瘤内的蓄积。此外,用自体免疫细胞衍生的膜包被将防止被巨噬细胞吞噬。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验